Cash, cash equivalents and short-term investments totaled $205.4M at September 30. “Our recent Phase 1b data support the potential of GSBR-1290 as a promising, differentiated oral GLP-1 receptor agonist with once-daily dosing,” said Raymond Stevens, Ph.D., Founder and CEO of Structure Therapeutics. “Following the completion of our recent $300 million equity financing in October, we believe we are well positioned to advance and accelerate the development of GSBR-1290 as well as our entire oral incretin franchise.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GPCR:
- Structure Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights
- Structure Therapeutics price target raised to $93 from $58 at Piper Sandler
- Five new option listings and one option delisting on October 25th
- Structure Therapeutics initiated with an Outperform at JMP Securities
- Structure Therapeutics management to meet with Piper Sandler